The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection
Darko Duplancic,1 Marijan Cesarik,2 Nikola Kolja Poljak,3 Maja Radman,4 Vedran Kovacic,5 Josipa Radic,5 Veljko Rogosic61Department of Cardiology, School of Medicine in Split, University Hospital Split, Split, Croatia; 2Department for Neurology, County General Hospital Pozega, Pozega, Croatia; 3Depar...
Guardado en:
Autores principales: | Duplancic D, Cesarik M, Poljak NK, Radman M, Kovacic V, Radic J, Rogosic V |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9ba1c67f428546559eb8d2127610992a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease
por: Priyanka S. Sagar, et al.
Publicado: (2021) -
Comparison between paricalcitol versus cinacalcet therapy in the management of secondary hyperparathyroidism among prevalent hemodialysis patients
por: Maha A. Behairy, et al.
Publicado: (2022) -
Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats
por: Farhad Koohpeyma, et al.
Publicado: (2021) -
Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology
por: Javier Díez, et al.
Publicado: (2021) -
Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease
por: Lilit V. Egshatyan, et al.
Publicado: (2018)